Welcome! Here you can find resources for healthcare providers ordering COVID-19 antibody infusions.
On April 16, 2021, the FDA revoked emergency use authorization for bamlanivimab monotherapy due to the increased prevalence of SARS-CoV-2 variants that are expected to be resistant to bamlanivimab administered alone. This change comes at the request of the manufacturer, Eli Lilly, due to the availability of more efficacious monoclonal antibody therapies, and is not related to any adverse events or safety issues. Bamlanivimab is still authorized for use when administered with etesevimab per the EUA. Infusion providers with remaining bamlanivimab inventory should contact AmerisourceBergen to order etesevimab to be paired with the remaining bamlanivimab. For more information, see the FDA’s Letter of Revocation, and Frequently Asked Questions on the Revocation of the Emergency Use Authorization for Bamlanivimab Administered Alone.
(Updated 5-20-21) This checklist is intended to help determine if treatment with COVID-19 antibody therapies are indicated in accordance with the Emergency Use Authorization (EUA).
If COVID-19 antibody therapies are not indicated, the checklist can be included in the medical record to document the clinical decision-making process.
If COVID-19 antibody therapies are indicated, the checklist can accompany the medication order to document eligibility criteria and support medical necessity. Please note: individual infusion site documentation requirements may vary.
Overview of necessary steps to refer a patient for COVID-19 antibody therapies. Please note: Individual infusion site documentation requirements may vary. (Updated 1-22-21)
-Infusion sites of care are encouraged to download and modify this checklist to create a custom checklist including any unique, site-specific requirements.
Regeneron Casirivimab + Imdevimab Emergency Use Authorization (EUA) Guidebook
NICA collaborated with Regeneron to develop this playbook with in-depth information about Casirivimab + Imdevimab